Physician profile
Casey Ikemire
NPI 1104426428
$2,520.25
in general payments reported to CMS, 2019-2025
35 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $614 · 2022: $518 · 2023: $627 · 2024: $423 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.30 | 2021-2025 | |
| Novo Nordisk INC | $315.41 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Mylan Specialty L.P. | $172.88 | 2021-2024 | Yupelri |
| Glaxosmithkline, LLC. | $168.01 | 2021-2023 | Trelegy Ellipta |
| Harmony Biosciences LLC | $157.51 | 2022-2024 | Wakix |
| Lilly USA, LLC | $156.75 | 2021-2024 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $140.76 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $135.64 | 2021-2024 | Tezspire, Airsupra |
| Jazz Pharmaceuticals INC. | $100.93 | 2021-2022 | |
| Pfizer INC. | $81.73 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $67.28 | 2022-2023 | Eliquis |
| Dexcom, INC. | $61.73 | 2023-2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $47.38 | 2023-2025 | Sunosi, Auvelity |
| Inspire Medical Systems, INC. | $46.04 | 2024-2025 | Inspire |
| Daiichi Sankyo INC. | $44.57 | 2021 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Ikemire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.